Intravenous cangrelor as a peri-procedural bridge with applied uses in ischemic events

Area of Science:

• Cardiology
• Pharmacology
• Interventional Cardiology

Background:

• Cangrelor is an adenosine triphosphate analogue antiplatelet agent.
• It is approved for percutaneous coronary intervention (PCI) to reduce peri-procedural myocardial infarction (MI), coronary revascularization, and stent thrombosis.

Purpose of the Study:

• To review the literature on cangrelor.
• To summarize its role as a peri-procedural bridge therapy.

Main Methods:

• Literature review of cangrelor's properties and clinical applications.
• Analysis of its pharmacokinetic and pharmacodynamic profile.

Main Results:

• Cangrelor reversibly inhibits adenosine diphosphate (ADP)-induced platelet aggregation.
• Platelet function is restored within 60 minutes of stopping therapy.
• It offers a balance between reducing ischemic events and minimizing bleeding risk.

Conclusions:

• Cangrelor is a valuable adjunct therapy in PCI.
• Its rapid reversibility makes it a promising bridge therapy for surgeries requiring temporary cessation of antiplatelet medication.